Prior notification of a concentration (Case M.8937 — Advent International/Zentiva) — Candidate case for simplified procedure (Text with EEA relevance.)
Date: 2018-06-19
Institutions: European Commission
Subjects: economic concentration, financial services, health care, investment company, leisure, mass media, merger control, pharmaceutical industry, retail trade, technology, telecommunications








C_2018214EN.01001101.xml










19.6.2018   


EN


Official Journal of the European Union


C 214/11





Prior notification of a concentration
(Case M.8937 — Advent International/Zentiva)
Candidate case for simplified procedure
(Text with EEA relevance)
(2018/C 214/10)

1.   
On 8 June 2018, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).
This notification concerns the following undertakings:






—


Advent International Corporation (‘Advent’, USA),










—


Zentiva group of companies, including Zentiva Pharma GmbH (Germany), Winthrop Arzneimittel GmbH (Germany), Winthrop Pharmaceuticals UK Ltd (UK), Zentiva France (France), Zentiva Polska sp. z.o.o. (Poland), Zentiva S.A. (Romania), Zentiva, a.s. (Slovakia), Zentiva International, a.s. (Slovakia), Zentiva Group, a.s. (Czech Republic), Zentiva, k.s. (Czech Republic), Zentiva Portugal, Lda (Portugal), Zentiva Italia S.r.l. (Italy), Zentiva GmbH (Austria), Helvepharm AG (Switzerland) and Zentiva HU Kft (Hungary) (together ‘Zentiva’), currently controlled by Sanofi.




The proposed concentration consists of the acquisition of sole control by Advent of Zentiva within the meaning of Article 3(1)(b) of the Merger Regulation.
The concentration is accomplished by way of purchase of shares.


2.   
The business activities of the undertakings concerned are:
—   for Advent: a global private equity investor, focused investments in several sectors, namely business and financial services; healthcare; industrial; retail, consumer and leisure; and technology, media and telecom.
—   for Zentiva: a pharmaceutical group focused on the development, manufacturing and marketing of generic pharmaceutical products primarily within Europe.


3.   
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.
Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.


4.   
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.8937 — Advent International/Zentiva
Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:





E-mail: COMP-MERGER-REGISTRY@ec.europa.eu




Fax +32 229-64301




Postal address:




European Commission




Directorate-General for Competition




Merger Registry




1049 Bruxelles/Brussel




BELGIQUE/BELGIË







(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2)  OJ C 366, 14.12.2013, p. 5.